Hadasit partnered with Pangea Biomed and Ultima Genomics for solid tumor cancer treatment research at Sharett Cancer Institute

Pangea Biomed partnered with Hadasit and Ultima Genomics for solid tumor cancer treatment research at Sharett Cancer Institute. As part of this clinical collaboration Hadassah will provide essential biological samples, conduct comprehensive patient follow-ups, and utilize their medical expertise to perform profound analysis of the data set, including DNA test results, clinical and patient data. “This collaboration allows us to combine our clinical expertise and patient data with Pangea Biomed’s advanced technological capabilities, enabling us to make more precise and personalized treatment decisions,” said Dr. Aron Popovtzer, Head of the Oncology Department at the Sharett Institute of Oncology.